Fabtech Technologies Ltd IPO

We are a key turnkey engineering solution provider in pharmaceuticals capex space, offering comprehensive start to finish solutions encompassing designing, engineering, procurement, installation and testing of pharmaceutical equipment for a wide range of customers. (Source: CRISIL Report). We offer services in greenfield projects for a wide range of customers primarily in the pharmaceutical, healthcare and biotech sector across various geographies, particularly key emerging economies. In such projects we offer end to end turnkey engineering services which range from disease identification until installation and commissioning of equipment. Additionally, we also offer some of our engineering solutions, which majorly include, equipment procurement and supply and logistics management, on a standalone basis, either as part of greenfield or brownfield projects. Our Company has adopted an asset light approach wherein we procure key equipment and materials for our projects from Related Entities to ensure that our projects are executed efficiently, to integrate our project execution operations and to reduce our dependence on third party suppliers. Our comprehensive solutions encompasses the entire project lifecycle of our customers and address the three key elements in pharmaceuticals, biotech and healthcare facilities, namely, bio clean air, clean water, and process. In addition to offering targeted solutions across the value chain, we also have an established track record in executing pharmaceutical projects across a diverse range of dosage forms, encompassing, liquids, solids, and semisolids. Our footprint spans more than 62 countries globally and across regions including but not limited to, Middle East, Africa, Asia, Europe, Latin America, North America, etc. (Source: CRISIL Report). Since incorporation and till July 31, 2025, our Company has completed fifty one (51) projects across countries, namely Saudi Arabia, Egypt, Algeria, Bangladesh, Ethiopia, Sri Lanka, United Arab Emirates.